BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how - 2Vote in favor of your Number one Kind of Gems
- 3Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- 4People Are Sharing The One Picture They Can't See Without Laughing, And It's The Comedy Spiral You Need Today
- 5Photos of amputees in Gaza, struggling to survive after losing limbs to Israeli airstrikes
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- Blood pressure drug recalled for possible cross-contamination
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- More than half way to the moon, the Artemis II astronauts are grappling with a toilet problem
- Must-See Attractions in Washington, D.C.
- Exhaustive Experiences into Prudent Senior Living in the UK
- Alice Wong, founder of the Disability Visibility Project, dies at 51
- French rapper Gims placed under investigation for 'aggravated money laundering'
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
